---
document_datetime: 2025-12-02 06:07:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/melatonin-neurim.html
document_name: melatonin-neurim.html
version: success
processing_time: 0.1058408
conversion_datetime: 2025-12-28 08:58:08.783366
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Melatonin Neurim

[RSS](/en/individual-human-medicine.xml/67618)

##### Authorised

This medicine is authorised for use in the European Union

melatonin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Melatonin Neurim](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Melatonin Neurim is a medicine used on its own for the short-term treatment of primary insomnia (poor quality of sleep) in patients aged 55 years or over. 'Primary' means that the insomnia does not have any identified cause, including any medical, mental or environmental cause.

Melatonin Neurim contains the active substance melatonin.

This medicine is the same as Circadin, which is already authorised in the EU. The company that makes Circadin has agreed that its scientific data can be used for Melatonin Neurim ('informed consent').

Expand section

Collapse section

## How is Melatonin Neurim used?

Melatonin Neurim can only be obtained with a prescription.

It is available as tablets; the recommended dose is one tablet a day, taken one to two hours before bedtime and after food. This dose can be continued for up to 13 weeks.

For more information about using Melatonin Neurim, see the package leaflet or contact your doctor or pharmacist.

## How does Melatonin Neurim work?

The active substance in Melatonin Neurim, melatonin, is a naturally occurring hormone, which is involved in coordinating the body's sleep cycle. Melatonin levels in the blood normally increase when it gets dark and peak in the middle of the night. Older people may produce less melatonin, leading to the development of insomnia. Melatonin Neurim increases their blood levels of melatonin, helping them to sleep. The active substance in Melatonin Neurim is released slowly over a few hours (prolonged-release tablets) which mimics the natural production of melatonin in the body.

## What benefits of Melatonin Neurim have been shown in studies?

Melatonin Neurim was more effective than placebo (a dummy treatment) at improving quality of sleep and the patients' ability to function normally on the following day in three main studies involving a total of 681 patients aged over 55 years with primary insomnia. The patients assessed the severity of their symptoms using a standard questionnaire after three weeks of treatment. When the results of all three studies were looked at together, 32% of the patients taking Melatonin Neurim (86 out of 265) reported a significant improvement in symptoms after three weeks, compared with 19% of those taking placebo (51 out of 272).

An additional study showed that Melatonin Neurim was more effective than placebo for at least 13 weeks.

## What are the risks associated with Melatonin Neurim?

The most common side effects with Melatonin Neurim (which may affect up to 1 in 100 people) include headache, nasopharyngitis (inflammation of the nose and throat), back pain and arthralgia (joint pain). These side effects were also common in those taking placebo.

For the full list of side effects and restrictions of Melatonin Neurim, see the package leaflet.

## Why is Melatonin Neurim authorised in the EU?

The European Medicines Agency decided that the benefits of Melatonin Neurim are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Melatonin Neurim?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Melatonin Neurim have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Melatonin Neurim are continuously monitored. Suspected side effects reported with Melatonin Neurim are carefully evaluated and any necessary action taken to protect patients.

## Other information about Melatonin Neurim

Melatonin Neurim received a marketing authorisation valid throughout the EU on 18 November 2022.

Melatonin Neurim : EPAR - Medicine Overview

Reference Number: EMA/858804/2022

English (EN) (117.89 KB - PDF)

**First published:** 23/11/2022

**Last updated:** 25/11/2022

[View](/en/documents/overview/melatonin-neurim-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-534)

български (BG) (143.36 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/bg/documents/overview/melatonin-neurim-epar-medicine-overview_bg.pdf)

español (ES) (119.16 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/es/documents/overview/melatonin-neurim-epar-medicine-overview_es.pdf)

čeština (CS) (140.24 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/cs/documents/overview/melatonin-neurim-epar-medicine-overview_cs.pdf)

dansk (DA) (118.7 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/da/documents/overview/melatonin-neurim-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.67 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/de/documents/overview/melatonin-neurim-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.96 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/et/documents/overview/melatonin-neurim-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.29 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/el/documents/overview/melatonin-neurim-epar-medicine-overview_el.pdf)

français (FR) (118.92 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/fr/documents/overview/melatonin-neurim-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.54 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/hr/documents/overview/melatonin-neurim-epar-medicine-overview_hr.pdf)

italiano (IT) (116.69 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/it/documents/overview/melatonin-neurim-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.22 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/lv/documents/overview/melatonin-neurim-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.91 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/lt/documents/overview/melatonin-neurim-epar-medicine-overview_lt.pdf)

magyar (HU) (138.45 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/hu/documents/overview/melatonin-neurim-epar-medicine-overview_hu.pdf)

Malti (MT) (142.4 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/mt/documents/overview/melatonin-neurim-epar-medicine-overview_mt.pdf)

Nederlands (NL) (117.59 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/nl/documents/overview/melatonin-neurim-epar-medicine-overview_nl.pdf)

polski (PL) (141.82 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/pl/documents/overview/melatonin-neurim-epar-medicine-overview_pl.pdf)

português (PT) (118.39 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/pt/documents/overview/melatonin-neurim-epar-medicine-overview_pt.pdf)

română (RO) (137.57 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/ro/documents/overview/melatonin-neurim-epar-medicine-overview_ro.pdf)

slovenčina (SK) (138.82 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/sk/documents/overview/melatonin-neurim-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.92 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/sl/documents/overview/melatonin-neurim-epar-medicine-overview_sl.pdf)

Suomi (FI) (115.16 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/fi/documents/overview/melatonin-neurim-epar-medicine-overview_fi.pdf)

svenska (SV) (115.67 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

25/11/2022

[View](/sv/documents/overview/melatonin-neurim-epar-medicine-overview_sv.pdf)

Melatonin Neurim : EPAR - Risk management plan summary

English (EN) (55.35 KB - PDF)

**First published:** 23/11/2022

[View](/en/documents/rmp-summary/melatonin-neurim-epar-risk-management-plan-summary_en.pdf)

## Product information

Melatonin Neurim : EPAR - Product Information

English (EN) (305.19 KB - PDF)

**First published:** 23/11/2022

**Last updated:** 14/09/2023

[View](/en/documents/product-information/melatonin-neurim-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-679)

български (BG) (356.86 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/bg/documents/product-information/melatonin-neurim-epar-product-information_bg.pdf)

español (ES) (324.64 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/es/documents/product-information/melatonin-neurim-epar-product-information_es.pdf)

čeština (CS) (350.57 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/cs/documents/product-information/melatonin-neurim-epar-product-information_cs.pdf)

dansk (DA) (278.47 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/da/documents/product-information/melatonin-neurim-epar-product-information_da.pdf)

Deutsch (DE) (328.83 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/de/documents/product-information/melatonin-neurim-epar-product-information_de.pdf)

eesti keel (ET) (326.58 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/et/documents/product-information/melatonin-neurim-epar-product-information_et.pdf)

ελληνικά (EL) (340.28 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/el/documents/product-information/melatonin-neurim-epar-product-information_el.pdf)

français (FR) (289.14 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/fr/documents/product-information/melatonin-neurim-epar-product-information_fr.pdf)

hrvatski (HR) (395.35 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/hr/documents/product-information/melatonin-neurim-epar-product-information_hr.pdf)

íslenska (IS) (317.88 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/is/documents/product-information/melatonin-neurim-epar-product-information_is.pdf)

italiano (IT) (312.72 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/it/documents/product-information/melatonin-neurim-epar-product-information_it.pdf)

latviešu valoda (LV) (330.46 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/lv/documents/product-information/melatonin-neurim-epar-product-information_lv.pdf)

lietuvių kalba (LT) (348.26 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/lt/documents/product-information/melatonin-neurim-epar-product-information_lt.pdf)

magyar (HU) (314.12 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/hu/documents/product-information/melatonin-neurim-epar-product-information_hu.pdf)

Malti (MT) (386.73 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/mt/documents/product-information/melatonin-neurim-epar-product-information_mt.pdf)

Nederlands (NL) (310.38 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/nl/documents/product-information/melatonin-neurim-epar-product-information_nl.pdf)

norsk (NO) (301.34 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/no/documents/product-information/melatonin-neurim-epar-product-information_no.pdf)

polski (PL) (386.91 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/pl/documents/product-information/melatonin-neurim-epar-product-information_pl.pdf)

português (PT) (315.17 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/pt/documents/product-information/melatonin-neurim-epar-product-information_pt.pdf)

română (RO) (389.16 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/ro/documents/product-information/melatonin-neurim-epar-product-information_ro.pdf)

slovenčina (SK) (324.62 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/sk/documents/product-information/melatonin-neurim-epar-product-information_sk.pdf)

slovenščina (SL) (320.26 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/sl/documents/product-information/melatonin-neurim-epar-product-information_sl.pdf)

Suomi (FI) (301.39 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/fi/documents/product-information/melatonin-neurim-epar-product-information_fi.pdf)

svenska (SV) (319.36 KB - PDF)

**First published:**

23/11/2022

**Last updated:**

14/09/2023

[View](/sv/documents/product-information/melatonin-neurim-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0002 14/09/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Melatonin Neurim : EPAR - All authorised presentations

English (EN) (38.39 KB - PDF)

**First published:** 23/11/2022

[View](/en/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-732)

български (BG) (51.72 KB - PDF)

**First published:**

23/11/2022

[View](/bg/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.28 KB - PDF)

**First published:**

23/11/2022

[View](/es/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.65 KB - PDF)

**First published:**

23/11/2022

[View](/cs/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.22 KB - PDF)

**First published:**

23/11/2022

[View](/da/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.85 KB - PDF)

**First published:**

23/11/2022

[View](/de/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (39.03 KB - PDF)

**First published:**

23/11/2022

[View](/et/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (51.43 KB - PDF)

**First published:**

23/11/2022

[View](/el/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_el.pdf)

français (FR) (38.96 KB - PDF)

**First published:**

23/11/2022

[View](/fr/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.25 KB - PDF)

**First published:**

23/11/2022

[View](/hr/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.79 KB - PDF)

**First published:**

23/11/2022

[View](/is/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_is.pdf)

italiano (IT) (38.17 KB - PDF)

**First published:**

23/11/2022

[View](/it/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.27 KB - PDF)

**First published:**

23/11/2022

[View](/lv/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.05 KB - PDF)

**First published:**

23/11/2022

[View](/lt/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.03 KB - PDF)

**First published:**

23/11/2022

[View](/hu/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.78 KB - PDF)

**First published:**

23/11/2022

[View](/mt/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.09 KB - PDF)

**First published:**

23/11/2022

[View](/nl/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.97 KB - PDF)

**First published:**

23/11/2022

[View](/no/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.18 KB - PDF)

**First published:**

23/11/2022

[View](/pl/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.46 KB - PDF)

**First published:**

23/11/2022

[View](/pt/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_pt.pdf)

română (RO) (44.8 KB - PDF)

**First published:**

23/11/2022

[View](/ro/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (52.83 KB - PDF)

**First published:**

23/11/2022

[View](/sk/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.34 KB - PDF)

**First published:**

23/11/2022

[View](/sl/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (37.86 KB - PDF)

**First published:**

23/11/2022

[View](/fi/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (38.45 KB - PDF)

**First published:**

23/11/2022

[View](/sv/documents/all-authorised-presentations/melatonin-neurim-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Melatonin Neurim Active substance melatonin International non-proprietary name (INN) or common name melatonin Therapeutic area (MeSH) Sleep Initiation and Maintenance Disorders Anatomical therapeutic chemical (ATC) code N05CH01

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Melatonin Neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

## Authorisation details

EMA product number EMEA/H/C/005603 Marketing authorisation holder

RAD Neurim Pharmaceuticals EEC SARL

4 rue de Marivaux

Opinion adopted 15/09/2022 Marketing authorisation issued 07/11/2022 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Melatonin Neurim : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (103.49 KB - PDF)

**First published:** 14/09/2023

[View](/en/documents/procedural-steps-after/melatonin-neurim-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Melatonin Neurim : EPAR - Public assessment report

Adopted

Reference Number: EMA/847216/2022

English (EN) (237.22 KB - PDF)

**First published:** 23/11/2022

[View](/en/documents/assessment-report/melatonin-neurim-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Melatonin Neurim

Adopted

Reference Number: EMA/CHMP/734993/2022

English (EN) (135.39 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-melatonin-neurim_en.pdf)

#### News on Melatonin Neurim

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

**This page was last updated on** 15/09/2023

## Share this page

[Back to top](#main-content)